16-18 July 2018 | Boston

 

2018 Speakers

Expand/Collapse

Shanthi Ganesh
Associate Director - Pre Clinical Oncology
Dicerna Pharmaceuticals

Day Two

Thursday July 20, 2017

15.30 | RNAi-Mediated Inhibition of β-Catenin Increases Responses to Multiple Immunotherapy Regimens across a Spectrum of Preclinical Tumor Models

Mithun Khattar
Scientist & Immuno- Oncology Lead
Takeda

Day One

Wednesday July 19, 2017

09.00 | Pre-clinical Modeling of Immune Responses to Cancer: From Bench- Side to Clinical Outcomes

Hon Leong
Associate Associate ProfessorProfessor
Mayo Clinic

Fu Li
Principal Scientist, Immunology
Seattle Genetics

Wen Lin
Senior Investigator I
Novartis Institutes for BioMedical Research

Matthew Lowerison
Postdoctoral Fellow
Mayo Clinic

Neil Michaud
Associate Director - Translational Medicine
EpiZyme

William Muller
Professor, Biochemistry
McGill University

Christopher L. Murrie
Associate Director, Research
OncoMed Pharmaceuticals, Inc.

Shuji Ogino
Professor and Chief of Program in MPE Molecular Pathological Epidemiology
Brigham and Women’s Hospital

Davy Ouyang
Senior Director
Crown Bioscience

Day One

Wednesday July 19, 2017

08.30 | Developing Checkpoint Target Humanized Models for Pre-clinical Efficacy Assessment

Daniel Powell
Associate Professor of Pathology & Laboratory Medicine
University of Pennsylvania, School of Medicine

Day Two

Thursday July 20, 2017

08.30 | Developing a Universal Immune Receptor Platform for Cancer Targeting

John Rhoden
Senior Research Scientist
Eli Lilly & Co

John M. Ruppert
MD PhD; Professor of Biochemistry & Jo and Ben Statler Chair of Breast Cancer Research
West Virginia University School of Medicine

Fangxian Sun
Lead Investigator - Research Pharmacology
Sanofi

David Teachey
Associate Professor of Paediatrics, Divisions of Haematology and Oncology
Children’s Hospital of Philadelphia

Day One

Wednesday July 19, 2017

16.00 | Highlighting Clinical Outcomes of CAR-T Therapies to Enhance Translational Insights from Preclinical Models

Alejandro Amador
Scientific Leader
GlaxoSmithKline

Jenni Bernoulli
Chief Operating Officer
Pharmatest Services

Michael Brehm
Associate Professor - Molecular Medicine
University of Massachusetts Medical School

Tom Brennan
Vice President, Pharmacology & Bioanalytics
Five Prime Therapeutics

Day Two

Thursday July 20, 2017

09.00 | Profiling Murine Tumor Models to Improve Translational Predictive Confidence for Immune-Based Therapeutics

Stephanie Busch
Scientist
uno Therapeutics

Day One

Wednesday July 19, 2017

15.30 | Strategies for Using Models in Engineered T Cell Research and Development

Zhao Chen
Investigator III
Genomics Institute of the Novartis Research Foundation (GNF)

Maryland Franklin
Vice President - Scientific Development
MI Bioresearch

Dmitry Gabrilovich
Professor & Program Leader - Translational Tumor Immunology Program
The Wistar Institute

Mark Whitmore
Associate Director
Palleon Pharmaceuticals

Day Two

Thursday July 20, 2017

15.00 | Targeting Glycan-Sensing Checkpoints to Unleash Both the Innate and Adaptive Immune Responses to Cancer

Matthew Hewitt
Principal Scientist & Director of Tumor Immunology & Microenvironment
Bellicum Pharmaceuticals

Rick Huntress
Director - Business Development, Clinical & In Vivo Services Business Development, Clinical & In Vivo Service
The Jackson Laboratory

Day One

Wednesday July 19, 2017

09.30 | Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice: A New Immuno-Oncology Platform

Saad Kenderian
Assistant Professor of Medicine and Oncology
Mayo Clinic

Day Two

Thursday July 20, 2017

09.30 | Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors